Longeveron Inc. (LGVN) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Miami, FL, 美国. 现任CEO为 Stephen H. Willard.
LGVN 拥有 IPO日期为 2021-02-12, 25 名全职员工, 在 NASDAQ Capital Marke, 市值为 $26.1M.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
